On March 6, 2024, analyst Andrew Mok from Barclays started covering Surgery Partners (NASDAQ: SGRY) with an Equal-Weight rating and a price target of $35. This update comes after Barclays had previously given Surgery Partners an Overweight recommendation. Surgery Partners is scheduled to release its earnings on February 19, 2024. Earlier, Barclays had lowered the price target for Surgery Partners to $56 from $69 but still maintained an Overweight rating.
Surgery Partners, Inc. (SGRY) Stock Analysis: March 6, 2024 Update
On March 6, 2024, Surgery Partners, Inc. (SGRY) had a relatively uneventful day in the stock market. The stock opened at $30.31, which was $0.19 lower than its previous close. Throughout the day, the price of SGRY shares remained flat, showing no change from the previous market close.
Looking at the overall performance of SGRY, the stock is currently trading in the middle of its 52-week range and below its 200-day simple moving average. This indicates that the stock has not experienced significant price movements in the short term and is trading below its long-term average price.
For investors considering SGRY, it may be worth monitoring the stock’s performance in the coming days to see if any significant developments occur that could potentially impact its price. Additionally, conducting thorough research on the company’s financials, industry trends, and competitive landscape can help investors make informed decisions about whether to buy, sell, or hold SGRY stock.
Surgery Partners, Inc. (SGRY) Stock Performance Analysis: Revenue Growth and Net Income Improvement
On March 6, 2024, Surgery Partners, Inc. (SGRY) stock performance was closely watched by investors and analysts following the release of its financial data. According to CNN Money, the company reported total revenue of $2.74 billion for the past year, with a quarterly total revenue of $735.40 million.
Compared to the previous year, Surgery Partners saw an 8.03% increase in total revenue, while total revenue remained flat since the last quarter. This indicates a steady performance in terms of revenue growth for the company.
In terms of net income, Surgery Partners reported a net loss of $11.90 million for the past year, with a net loss of $1.00 million for the last quarter. Despite the losses, the company saw a significant improvement in net income, with a 78.21% increase since the previous year. Net income also remained stable, with a 0.0% increase since the last quarter.
Earnings per share (EPS) for Surgery Partners were reported at -$0.09 for the past year and -$0.01 for the last quarter. The company experienced an 84.05% increase in EPS since the previous year, with no change in EPS since the last quarter.
Overall, Surgery Partners showed positive growth in terms of revenue and net income, indicating a strong performance for the company. Despite the losses reported, the significant improvements in net income and EPS demonstrate the company’s ability to navigate challenges and drive growth. Investors and analysts will continue to monitor Surgery Partners’ performance to assess its future potential in the market.
